Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model

Journal of Clinical Investigation

Volumn 126, Issue 5, 2016, Pages 1871-1884

  Komla Ebri, Davide ^a   Dambroise, Emilie ^a   Kramer, Ina ^b   Benoist Lasselin, Catherine ^a   Kaci, Nabil ^a   Gall, Cindy Le ^a   Martin, Ludovic ^a   Busca, Patricia ^c   Barbault, Florent ^c   Graus Porta, Diana ^b   Munnich, Arnold ^a,d   Kneissel, Michaela ^b   Rocco, Federico Di ^a   Biosse Duplan, Martin ^a,e   Legeai Mallet, Laurence ^a,d  

^a IMAGINE INSTITUTE   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e Paris 5 Descartes University EA 2496 U F R of Odontology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; INFIGRATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C GAMMA; STAT1 PROTEIN; TRANSCRIPTION FACTOR SOX9; 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-(4-(4-ETHYLPIPERAZIN-1-YL)-PHENYLAMINO)PYRIMIDIN-4-YL)-1-METHYLUREA; CARBANILAMIDE DERIVATIVE; FGFR3 PROTEIN, MOUSE; PYRIMIDINE DERIVATIVE; SOX9 PROTEIN, MOUSE; STAT1 PROTEIN, MOUSE;

ACHONDROPLASIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APPENDICULAR SKELETON; ARTICLE; AXIAL SKELETON; BONE GROWTH; CALVARIA; CARTILAGE CELL; CONTROLLED STUDY; EMBRYO; FEMUR; FORAMEN MAGNUM; GROWTH PLATE; HUMAN; HUMAN CELL; INTERVERTEBRAL DISK DISEASE; LOW DRUG DOSE; LUMBAR VERTEBRA; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SKELETON; SKULL DEFECT; ANIMAL; CHONDROCYTE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; INTERVERTEBRAL DISK; MAPK SIGNALING; METABOLISM; MUTANT MOUSE STRAIN; PATHOLOGY; TRANSFORMED CELL LINE;

ACHONDROPLASIA; ANIMALS; CELL LINE, TRANSFORMED; CHONDROCYTES; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; INTERVERTEBRAL DISC; LUMBAR VERTEBRAE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, MUTANT STRAINS; PHENYLUREA COMPOUNDS; PHOSPHOLIPASE C GAMMA; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SOX9 TRANSCRIPTION FACTOR; STAT1 TRANSCRIPTION FACTOR;

EID: 84988498946     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI83926     Document Type: Article

References (52)

1. Baujat G, Legeai-Mallet L, Finidori G, Cormier-Daire V, Le Merrer M. Achondroplasia. Best Pract Res Clin Rheumatol. 2008;22(1):3-18.
2. Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370(9582):162-172.
3. Rousseau F, et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature. 1994;371(6494):252-254.
4. Shiang R, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell. 1994;78(2):335-342.
5. Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet. 1996;12(4):390-397.
6. Pannier S, et al. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia. Bone. 2010;47(5):905-915.
7. Naski MC, Colvin JS, Coffin JD, Ornitz DM. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development. 1998;125(24):4977-4988.
8. Iwata T, et al. A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos. Hum Mol Genet. 2000;9(11):1603-1613.
9. Legeai-Mallet L, Benoist-Lasselin C, Munnich A, Bonaventure J. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Bone. 2004;34(1):26-36.
10. Minina E, Kreschel C, Naski MC, Ornitz DM, Vortkamp A. Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell. 2002;3(3):439-449.
11. Zhou ZQ, Ota S, Deng C, Akiyama H, Hurlin PJ. Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes. Hum Mol Genet. 2015;24(6):1764-1773.
12. Murakami S, et al. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype. Genes Dev. 2004;18(3):290-305.
13. Nowroozi N, et al. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Hum Mol Genet. 2005;14(11):1529-1538.
14. Wendt DJ, et al. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J Pharmacol Exp Ther. 2015;353(1):132-149.
15. Lorget F, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91(6):1108-1114.
16. Xie Y, et al. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia. Hum Mol Genet. 2012;21(18):3941-3955.
17. Garcia S, et al. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice. Sci Transl Med. 2013;5(203):203ra124.
18. Yamashita A, et al. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature. 2014;513(7519):507-511.
19. Matsushita M, et al. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene. Endocrinology. 2015;156(2):548-554.
20. Guagnano V, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methylurea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011;54(20):7066-7083.
21. Gudernova I, et al. Multikinase activity of fibroblast growth factor receptor (FGFR) inhibitors SU5402, PD173074, AZD1480, AZD4547 and BGJ398 compromises the use of small chemicals targeting FGFR catalytic activity for therapy of short stature syndromes. Hum Mol Genet. 2016;25(1):9-23.
22. Wöhrle S, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013;28(4):899-911.
23. Wöhrle S, et al. Fibroblast growth factor receptors as novel therapeutic targets in SNF5-deleted malignant rhabdoid tumors. PLoS One. 2013;8(10):e77652.
24. Scheller T, et al. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br J Cancer. 2015;112(5):841-850.
25. Benoist-Lasselin C, et al. Human immortalized chondrocytes carrying heterozygous FGFR3 mutations: an in vitro model to study chondrodysplasias. FEBS Lett. 2007;581(14):2593-2598.
26. Gibbs L, Legeai-Mallet L. FGFR3 intracellular mutations induce tyrosine phosphorylation in the Golgi and defective glycosylation. Biochim Biophys Acta. 2007;1773(4):502-512.
27. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002;16(12):1446-1465.
28. Di Rocco F, et al. FGFR3 mutation causes abnormal membranous ossification in achondroplasia. Hum Mol Genet. 2014;23(11):2914-2925.
29. Pannier S, et al. Activating Fgfr3 Y367C mutation causes hearing loss and inner ear defect in a mouse model of chondrodysplasia. Biochim Biophys Acta. 2009;1792(2):140-147.
30. Jonquoy A, et al. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model. Hum Mol Genet. 2012;21(4):841-851.
31. Chan WC, Au TY, Tam V, Cheah KS, Chan D. Coming together is a beginning: the making of an intervertebral disc. Birth Defects Res C Embryo Today. 2014;102(1):83-100.
32. Ornitz DM, Marie PJ. Fibroblast growth factor signaling in skeletal development and disease. Genes Dev. 2015;29(14):1463-1486.
33. Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. J Biol Chem. 1998;273(21):13007-13014.
34. Krejci P, et al. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One. 2008;3(12):e3961.
35. Lefebvre V, Huang W, Harley VR, Goodfellow PN, de Crombrugghe B. SOX9 is a potent activator of the chondrocyte-specific enhancer of the pro alpha1(II) collagen gene. Mol Cell Biol. 1997;17(4):2336-2346.
36. Lefebvre V, de Crombrugghe B. Toward understanding SOX9 function in chondrocyte differentiation. Matrix Biol. 1998;16(9):529-540.
37. Sahni M, et al. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 1999;13(11):1361-1366.
38. Sahni M, Raz R, Coffin JD, Levy D, Basilico C. STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development. 2001;128(11):2119-2129.
39. Muenke M, et al. A unique point mutation in the fibroblast growth factor receptor 3 gene (FGFR3) defines a new craniosynostosis syndrome. Am J Hum Genet. 1997;60(3):555-564.
40. Cappellen D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23(1):18-20.
41. Chesi M, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92(9):3025-3034.
42. Carter EP, Fearon AE, Grose RP. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. 2015;25(4):221-233.
43. Mugniery E, et al. An activating Fgfr3 mutation affects trabecular bone formation via a paracrine mechanism during growth. Hum Mol Genet. 2012;21(11):2503-2513.
44. Sebastian A, et al. Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal. J Orthop Res. 2011;29(3):375-379.
45. Trudel S, et al. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood. 2004;103(9):3521-3528.
46. Grand EK, Chase AJ, Heath C, Rahemtulla A, Cross NCP. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia. 2004;18(5):962-966.
47. De Brito LR, et al. Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leuk Res. 2011;35(9):1233-1240.
48. Aviezer D, Golembo M, Yayon A. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia - genetic short limbed dwarfism. Curr Drug Targets. 2003;4(5):353-365.
49. Reina V, et al. Craniovertebral junction anomalies in achondroplastic children. Adv Tech Stand Neurosurg. 2014;40:295-312.
50. Julliand S, et al. Lung function, diagnosis, and treatment of sleep-disordered breathing in children with achondroplasia. Am J Med Genet A. 2012;158A(8):1987-1993.
51. Engberts AC, Jacobs WC, Castelijns SJ, Castelein RM, Vleggeert-Lankamp CL. The prevalence of thoracolumbar kyphosis in achondroplasia: a systematic review. J Child Orthop. 2012;6(1):69-73.
52. Jeong ST, Song HR, Keny SM, Telang SS, Suh SW, Hong SJ. MRI study of the lumbar spine in achondroplasia. A morphometric analysis for the evaluation of stenosis of the canal. J Bone Joint Surg Br. 2006;88(9):1192-1196.